Inflammation plays a role in the pathogenesis of heart failure. Neopterin, pteridine, synthesized mainly by activated macrophages, is a marker of inflammation, activation of the immune system, and an active participant in cardiovascular disease. Measuring neopterin levels can help track the evolution of specific inflammatory conditions. In addition, neopterin was associated with cardiac dysfunction after cardiac surgery and improved the accuracy of predicting the risk of postoperative cardiac dysfunction. In this review, we provide current insights into neopterin and its relationship to heart failure.

This article analyzes the frequency and features of cardiac amyloidosis in the elderly. The morphology and pathogenesis of amyloid cardiomyopathy are presented. The features of the clinical picture of the heart and aortic lesions in systemic and local variants of amyloidosis are analyzed. Polymorbidity in older people, which complicates the diagnosis of cardiac amyloidosis and leads to a delay in treatment, is reviewed. The diagnostic methods of various types of cardiac amyloidosis are evaluated. Modern trends in the treatment of amyloidosis are presented.

almost overlapped beyond their anatomical sites. The miPD-L1-positive cases showed significantly better OS compared to the negative cases in both gastric and intestinal DLBCL (P=0.0430 and P=0.0115). DEL was found in 11 gastric (9%) and 6 intestinal cases (12%), with significantly worse OS than the others in each anatomical group (P=0.0012 and P=0.0008, respectively). Among patients with complete remission, 21 (16%) of 134 gastric and 6 (17%) of 36 intestinal DLBCL patients had recurrence. Differences in survival, calculated from recurrence, were significant between gastric DLBCL patients with and without POD24 (P=0.0427), but did not work in prognostic delineation of intestinal cases (P=0.563). Multivariate analysis revealed that advanced Lugano stage (P<0.001), DEL (P<0.001), and miPD-L1 negativity (<20%, P=0.027), but not intestinal site (P=0.171), were significant prognostic factors for OS of giDLBCL. Conclusion:The anatomical site of disease did not influence outcome in giDLBCL in the rituximab era. Lugano stage, PD-L1 expression on microenvironment immune cells, and MYC/BCL2 co-expression provide therapeutic guidance for patients with giDLBCL.

Russian Federation; 4 Therapy, Clinical Hospital by V.M. Buyanova, Moscow, Russian Federation; 5 Radiology, Clinical Hospital by V.M. Buyanova, Moscow, Russian Federation Currently the association between hepatitis C virus and DLBCL widely accepted. The result of evidence from epidemiological and clinical studies carried out in the last decades. The majority of studies are ABSTRACT 439 related to antiviral therapy (AT) consisting of interferon (IFN) and ribavirin (RBV). New antiviral regimes without interferon allowed to obtain a high percentage of cure of patients from viral infection. There were limited data about efficacy of the new direct-acting antiviral agents (DAAs) in the treatment of patients DLBCL+HCV. The research objective is to analyze clinical, laboratory, morphological parameters and treatment results in patients with DLBCL+HCV who received DAA together with chemotherapy. Our study included 16 patients with DLBCL+HCV, who received DAA and immunohypotherapy (R-CHOP) from 2016 to 2019 at National Medical Research Center of Oncology named after N. N. Blokhin and Russian National Research Medical University named after N.I. Pirogov. The median age of patients was 48 years (32-75). Man/ woman ratio of was 10/6. All 16 patients had III-IV stages. Bsymptoms were present in 50% (8) of patients. Bulk disease occurred in 62%(10) of patients. Histological variants: 3 patients had GCB type DLCBCL, 13 patients -non-GCB type DLBCL. Spleen lesion was present in 37%(6) patients, bone marrow -in 31% (5) of patients, liver lesion -in 37%(6) of patients. Hb≤14,0g/dl were found in 37% (6) and platelets ≤100x10 9 /l in 25%(4) of patients. Before the treatment:increase level of LDH ≥450 IU/l was in 81%(13) of patients, ALT ≥40 (7) of patients, and albumin ≤35g/l in 37% (6) of patients. HCV RNA were detect in blood of all patients. In all patients the viral RNA was more then 1.6x10 6 IU/l. The 1st genotype of the virus was found in 63%(10) of patients. Before immunochemotherapy all patients received DAA therapy, according on the virus genotype. After 30 days of DAA therapy virology remission obtained in 94%(15) of patients. The level of ALT≤40 IU/l decreased at 81%(13) patients, AST ≤40 IU/l-62%(10) patients. DAA conducted during 4-6 months together with immunochemotherapy. The total response (ORR) of R-CHOP+DAA therapy was 50%. The 2-year survival without progression of the disease (PFS) was 25%. Median follow-up was 24 months. 56% of patients had a relapse of lymphoma. Median of OS was 20 months. Median DFS was 11 months. Conclusion: DAAs therapy makes it possible to complete the therapy program without complications for all patients with DLBCL + HCV. Safety, rapidity and efficacy of DAA in obtaining a virological response, as well as a good profile of tolerance DAA therapy can be used in combination with chemotherapy. Objective: To examine the efficacy of haploidentical stem-cell transplantation (haplo-SCT) for patients with refractory relapsed(R/R) aggressive non-Hodgkin lymphoma (NHL) by comparing with those who con...

Analysis was made of the demographic characteristics, initial hematological and biochemical parameters, splenectomy history, presence of organomegaly and LAP, bone marrow (BM) fibrosis, and the clinical and biological presentation at the time of HCL diagnosis.BM biopsy was performed at 3-6 months after cladribine treatment for response evaluation. Results: The total 65 HCL patients comprised 47 (72.2%) males and 18 (27.3%) females with a median age of 53.6 years (range, 34-80 years). The median follow-up duration was 62.8 months (range: 5.7-229.3 months). Splenectomy was determined in the medical history of 2 patients with an unknown etiology.Cladribine monotherapy was administered as first-line treatment in 60 patients (92.3%), and 5 patients (7.7%) who did not meet the treatment criteria were followed up without treatment. Of the treated patients, CR was achieved in 54 patients (90%), and PR was achieved in 3 patients (5%) with the overall response rate (CR+PR) of 95%. SD was determined in the remaining 3 patients (5%) after first-line therapy. A total of 16 (24.4 %) patients either relapsed or progressed, with a median progression-free survival of 47 months (25-112 months). The analysis results showed that patients with relapse or progressive disease had higher LDH levels at the time of diagnosis than patients without relapse or progression (p:0.01).With the exception of lactate dehydrogenase (LDH) level at diagnosis, no significant difference was determined between these groups in respect of spleen and liver size, peripheral LAP, BM fibrosis score, hematological parameters, vitamin B12, ferritin levels, sedimentation and flow cytometric results Summary/Conclusion: This study demonstrated that an initial elevated LDH level is associated with a worse outcome in HCL patients. Patients with higher LDH levels may experience relapse or progression more frequently, therefore, the LDH level should be taken into account when deciding on treatment and those patients should be monitored more carefully. Aggressive treatment approaches such as combination therapies with monoclonal antibodies and PA may be considered as induction treatment. LDH level can be recommended for use as an inexpensive and easily available biomarker for risk assessment of HCL patients at onset.